• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Upexi Reports Fiscal Second Quarter 2026 Financial Results

    2/10/26 4:35:00 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $UPXI alert in real time by email

    Digital Asset Revenue was $5.1 Million for the Quarter

    Gross Profit Increased 126% YoY to $6.7 Million for the Quarter

    Conference Call Scheduled for Today, February 10, 2026, at 5:30 p.m. Eastern Time

    TAMPA, Fla., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"),  a leading Solana-focused digital asset treasury company and consumer brands owner, today announced its financial results for the fiscal second quarter ended December 31, 2025.

    "Our conviction in the long-term opportunity for Solana and our strategy remains stronger than ever despite the challenging market environment over the last several months - dynamics which we view as cyclical, not structural," said Allan Marshall, Chief Executive Officer of Upexi. "During the quarter, we continued to drive our business forward by delivering $5.1 million of digital asset revenue, raising approximately $10 million from a private placement, and implementing a $50 million share repurchase program. We remain encouraged by the increased development, usage and adoption of Solana across the financial landscape and have continued to grow our Solana holdings on a per-share basis. We believe we are well-positioned with a scalable model designed to drive sustainable growth, cash flow, and value creation over time for our shareholders."

    Financial Highlights for the Quarter Ended December 31, 2025

    • Total revenue for the quarter was approximately $8.1 million, compared to $4.0 million for the same quarter ended December 31, 2024.
      • Revenue from operations from the consumer brands business totaled $2.9 million.
      • Digital asset revenue, which primarily consists of staking income, totaled $5.1 million.
    • Gross profit totaled $6.7 million, up 126% year-over-year, due mainly to the addition of the digital asset treasury business.
    • Net loss totaled $178.9 million, or $2.94 per share, compared to a net loss of $1.3 million, or $(1.24) per share, for the quarter ended December 31, 2024. This net loss was largely driven by $164.5 million of unrealized losses on digital assets, reflecting non-cash quarter-end fair value adjustments, as well as $8.3 million of stock-based compensation expense.
    • Cash and cash equivalents were $1.6 million as of December 31, 2025.
    • As of February 9, 2026, the Company had 69,760,581 shares of common stock outstanding.



    Operational and Other Highlights Subsequent to the Quarter

    • Announced forthcoming strategic shift to a high-return treasury strategy.
    • Previously-filed shelf registration statement on Form S-3 went effective.
    • Announced the pricing of a $36 million private placement convertible note in exchange for locked Solana.
    • Announced the pricing of a $7.4 million registered direct offering.
    • Current cash on hand stands at approximately $9.7 million.



    The Company's Quarterly Report on Form 10-Q for this period is available on the SEC's website and on Upexi's IR website.

    Conference Call Information

    Event:Fiscal Second Quarter 2026 Earnings Call
    Date:Tuesday, February 10, 2026
    Time:5:30 p.m. ET
    Live Call:1-877-407-9716 (U.S. Toll-Free) or 1-201-493-6779 (International)
    Webcasthttps://ir.upexi.com/news-events/ir-calendar

      

    For interested individuals unable to join the conference call, a dial-in replay of the call will be available until February 24, 2026, and can be accessed by dialing 1-844-512-2921 (U.S. Toll Free) or 1-412-317-6671 (International) and entering replay pin number: 13758450.

    About Upexi, Inc.

    Upexi, Inc. (NASDAQ:UPXI) is a leading digital asset treasury company, where it aims to acquire and hold as much Solana (SOL) as possible in a disciplined and accretive fashion. In addition to benefiting from the potential price appreciation of Solana - the cryptocurrency of the leading high-performance blockchain - Upexi utilizes three key value accrual mechanisms in intelligent capital issuance, staking, and discounted locked token purchases. The Company operates in a risk-prudent fashion to position itself for any market environment and to appeal to investors of all kinds, and it currently holds over two million SOL. Upexi also continues to be a brand owner specializing in the development, manufacturing, and distribution of consumer products. Please see www.upexi.com for more information.

    Follow Upexi on X - https://x.com/upexitreasury

    Follow CEO, Allan Marshall, on X - https://x.com/upexiallan

    Follow CSO, Brian Rudick, on X - https://x.com/thetinyant

    Forward-Looking Statements

    This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations, or intentions regarding the future. For example, the Company is using forward looking statements when it discusses the anticipated use of proceeds. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with business strategy, potential acquisitions, revenue guidance, product development, integration, and synergies of acquiring companies and personnel. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward- looking statements. Although we believe that the beliefs, plans, expectations, and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

    Company Contact

    Brian Rudick, Chief Strategy Officer

    Email: brian.rudick@upexi.com

    Phone: (203) 442-5391

    Investor Relations Contact

    KCSA Strategic Communications

    Valter Pinto or Jack Perkins

    Upexi@KCSA.com

    Media Relations Inquiries

    Greg or Katie @STiR-communications.com

    STiR-communications.com

     
    UPEXI, INC.

    CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

           
      December 31,  June 30, 
      2025  2025 
      (Unaudited)    
    ASSETS      
    Current assets      
    Cash $1,616,765  $2,975,150 
    Accounts receivable, net  594,552   157,515 
    Inventory, net  728,273   1,152,870 
    Due from VitaMedica transition  304,880   228,017 
    Prepaid expenses and other receivables  1,302,064   350,836 
    Current digital assets at fair value  164,703,917   49,913,655 
    Purchase price receivable - VitaMedica  2,000,000   2,000,000 
    Total current assets  171,250,451   56,778,043 
             
    Property and equipment, net  543,246   2,052,573 
    Intangible assets, net  874,733   163,113 
    Goodwill  673,854   848,854 
    Deferred tax asset  5,948,858   5,948,858 
    Digital assets at fair value, net of current  90,998,464   56,083,525 
    Other assets  218,710   192,123 
    Right-of-use asset, net

      636,449   1,739,755 
    Total other assets

      99,894,314   67,028,801 
             
    Total assets

     $271,144,765  $123,806,844 
             
    LIABILITIES AND STOCKHOLDERS' EQUITY        
    Current liabilities        
    Accounts payable $665,840  $1,039,370 
    Accrued compensation  3,111,115   3,470,296 
    Deferred revenue  47,287   13,155 
    Accrued liabilities  1,964,281   356,064 
    Accrued interest  2,902,942   792,449 
    Acquisition payable  260,652   260,652 
    Current portion of promissory notes  560,000   560,000 
    Short-term treasury debt  62,695,723   20,000,000 
    Current portion of Cygnet subsidiary notes payable  5,380,910   5,380,910 
    Current portion of operating lease payable  263,672   691,010 
    Total current liabilities  77,852,422   32,563,906 
             
    Operating lease payable, net of current portion  460,134   1,145,440 
    Convertible notes payable  144,115,480   - 
             
    Total long-term liabilities  144,575,614   1,145,440 

      

    Stockholders' equity      
    Preferred stock, $0.00001 par value, 10,000,000 shares authorized, and 150,000 and 150,000 shares issued and outstanding, respectively  2   2 
    Common stock, $0.00001 par value, 1,000,000,000 shares authorized, and 63,212,588 and 38,270,571 shares issued, respectively  632   383 
    Treasury stock, 416,226 and 0, as of December 31, 2025, and June 30, 2025, respectively  (799,277)  - 
             
    Additional paid in capital  222,236,002   150,640,935 
    Accumulated deficit  (172,720,630)  (60,543,822)
    Total stockholders' equity

      48,716,729   90,097,498 
             
    Total liabilities and stockholders' equity

     $271,144,765  $123,806,844 
             

       

     
    UPEXI, INC.
    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
           
      Three Months Ended December 31,  Six Months Ended December 31, 
      2025  2024  2025  2024 
                 
    Revenue            
    Revenue $2,908,527  $4,005,492  $6,064,655  $8,362,007 
    Digital asset revenue  5,143,513   -   11,227,130   - 
    Total revenue  8,052,040   4,005,492   17,291,785   8,362,007 
                     
    Cost of revenue  1,340,881   1,031,386   2,297,626   2,457,833 
                     
    Gross profit  6,711,159   2,974,106   14,994,159   5,904,174 
                     
    Operating expenses                
    Sales and marketing  915,841   949,963   1,983,396   1,991,388 
    Distribution costs  924,201   1,276,422   1,811,797   2,732,147 
    General and administrative  5,522,786   1,548,590   14,779,994   2,916,280 
    Unrealized loss on digital assets  164,495,019   -   86,498,895   - 
    Realized loss on digital asset revenue conversion to USD  341,599   -   341,599   - 
    Stock-based compensation  8,300,673   32,578   14,057,071   173,876 
    Amortization of acquired intangible assets  19,190   19,190   38,380   38,380 
    Impairment on assets from manufacturing shut down  1,422,289   -   1,422,289   - 
    Depreciation  134,388   220,562   270,290   460,467 
       182,075,986   4,047,305   121,203,711   8,312,538 
                     
    Loss from operations  (175,364,827)  (1,073,199)  (106,209,552)  (2,408,364)
                     
    Other expense, net                
    Interest expense, net  (3,604,709)  (228,111)  (6,304,092)  (518,523)
    Other income, net  44,606   -   336,836   - 
    Other expense, net  (3,560,103)  (228,111)  (5,967,256)  (518,523)
                     
    Loss on operations before income tax  (178,924,930)  (1,301,310)  (112,176,808)  (2,926,887)
                     
    Income tax benefit (expense)  -   -   -   - 
                     
    Net loss $(178,924,930) $(1,301,310) $(112,176,808) $(2,926,887)
                     
    Basic loss per share:                
    Loss per share $(2.94) $(1.24) $(1.93) $(2.80)
                     
    Diluted loss per share:                
    Loss per share $(2.94) $(1.24) $(1.93) $(2.80)
                     
    Basic weighted average shares outstanding  60,829,603   1,045,429   58,085,114   1,045,429 
    Fully diluted weighted average shares outstanding  60,829,603   1,045,429   58,085,114   1,045,429 
                     





    Primary Logo

    Get the next $UPXI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $UPXI

    DatePrice TargetRatingAnalyst
    8/4/2025$15.00Buy
    Alliance Global Partners
    6/16/2025$16.00Neutral → Overweight
    Cantor Fitzgerald
    More analyst ratings

    $UPXI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Upexi Reports Fiscal Second Quarter 2026 Financial Results

    Digital Asset Revenue was $5.1 Million for the Quarter Gross Profit Increased 126% YoY to $6.7 Million for the Quarter Conference Call Scheduled for Today, February 10, 2026, at 5:30 p.m. Eastern Time TAMPA, Fla., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"),  a leading Solana-focused digital asset treasury company and consumer brands owner, today announced its financial results for the fiscal second quarter ended December 31, 2025. "Our conviction in the long-term opportunity for Solana and our strategy remains stronger than ever despite the challenging market environment over the last several months - dynamics which we view as cyclical, not s

    2/10/26 4:35:00 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi to Participate in A.G.P.'s Digital Asset Innovation Summit on February 22-25

    TAMPA, Fla., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) ("Upexi" or the "Company"), a leading Solana-focused digital asset treasury company and consumer brands owner, today announced that management will participate in one-on-one investor meetings at A.G.P.'s Digital Asset Innovation Summit on February 22-25, 2026, at the Park Hyatt in Beaver Creek, Colorado. A.G.P.'s Digital Asset Innovation SummitDate: February 22-25, 2026Location: Park Hyatt, Beaver Creek, ColoradoAttendees: Brian Rudick, Chief Strategy OfficerFormat: Investor Meetings To schedule a one-on-one meeting with Upexi's management team, please contact KCSA Strategic Communications at Upexi@KCSA.com. About

    2/9/26 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Announces Pricing of $7.4 Million Registered Direct Offering With a Single Institutional Investor

    TAMPA, Fla., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a leading Solana-focused digital asset treasury company and consumer brands owner, today announced that it has entered into a definitive agreement with a single institutional investor for the sale and issuance of 6,337,000 shares of common stock of the Company and warrants to purchase up to 6,337,000 shares of common stock at a combined offering price of $1.17 per share of common stock and accompanying warrant, in a registered direct offering. The warrants have an exercise price of $1.50 per share, will be exercisable immediately upon issuance, and will expire five (5) years following the d

    2/6/26 8:33:38 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    SEC Filings

    View All

    Upexi Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - UPEXI, INC. (0001775194) (Filer)

    2/10/26 5:15:30 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by Upexi Inc.

    10-Q - UPEXI, INC. (0001775194) (Filer)

    2/10/26 4:46:01 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - UPEXI, INC. (0001775194) (Filer)

    2/9/26 5:17:23 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Marshall Allan bought $90,000 worth of shares (50,000 units at $1.80), increasing direct ownership by 1% to 4,046,261 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    12/23/25 7:53:48 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Executive Officer Marshall Allan was granted 1,600,000 shares and bought $310,500 worth of shares (150,000 units at $2.07), increasing direct ownership by 78% to 3,996,261 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    12/17/25 6:43:21 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Salkind Gene bought $127,500 worth of shares (50,000 units at $2.55) (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    11/21/25 6:32:50 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Marshall Allan bought $90,000 worth of shares (50,000 units at $1.80), increasing direct ownership by 1% to 4,046,261 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    12/23/25 7:53:48 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Executive Officer Marshall Allan was granted 1,600,000 shares and bought $310,500 worth of shares (150,000 units at $2.07), increasing direct ownership by 78% to 3,996,261 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    12/17/25 6:43:21 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Salkind Gene bought $127,500 worth of shares (50,000 units at $2.55) (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    11/21/25 6:32:50 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alliance Global Partners initiated coverage on Upexi, Inc. with a new price target

    Alliance Global Partners initiated coverage of Upexi, Inc. with a rating of Buy and set a new price target of $15.00

    8/4/25 8:09:26 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi, Inc. upgraded by Cantor Fitzgerald with a new price target

    Cantor Fitzgerald upgraded Upexi, Inc. from Neutral to Overweight and set a new price target of $16.00

    6/16/25 7:42:40 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Leadership Updates

    Live Leadership Updates

    View All

    Upexi Welcomes Jon Najarian to the Upexi Advisory Committee

    TAMPA, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI), a brand owner specializing in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space, today announced the addition of Jon Najarian (Twitter: @jonnajarian) to the Upexi Advisory Committee, joining Arthur Hayes and S◎L Big Brain as founding Upexi Advisory Committee members. Jon Najarian is a highly influential figure in the world of finance, renowned for his deep expertise in options trading and market strategy. A former professional football player, Jon co-founded options trading firm Mercury Trading and later launched financial education company Marke

    10/23/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Establishes Advisory Committee and Welcomes Arthur Hayes as First Member

    Additional members to join the Advisory Committee in the coming weeks to optimize performance, increase visibility and unlock capital raising opportunities Arthur brings deep expertise, exposure and connectivity to both digital assets and traditional finance TAMPA, Fla., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products with diversification into the cryptocurrency space, today announced the establishment of the Upexi Advisory Committee, composed of highly prominent individuals from the digital assets and traditional finance industries. Upexi will seek t

    8/12/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Financials

    Live finance-specific insights

    View All

    Upexi to Host Second Quarter 2026 Earnings Call on February 10th at 5:30 p.m. ET

    TAMPA, Fla., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a leading Solana-focused digital asset treasury company and consumer brands owner, today announced that it plans to host a conference call and report its financial results for the second quarter 2026 ended December 31, 2025, on Tuesday, February 10, 2026. Additional details are available under the Investor Relations section of the Company's website: https://ir.upexi.com/ Event:Upexi Second Quarter 2026 Earnings CallDate:Tuesday, February 10, 2026Time:5:30 p.m. ETLive Call:1-877-407-9716 (U.S. Toll-Free) or 1-201-493-6779 (International)Webcasthttps://ir.upexi.com/news-events/ir-calendar For

    1/29/26 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Reports Record Digital Asset Revenue for Fiscal First Quarter 2026

    Digital Asset Revenue was Approximately $6.1 Million for the Quarter Gross Profit Totaled $8.3 Million, up 183% Year-Over-Year Net Income Increased to $66.7 Million, Compared to a Net Loss of $1.6 Million, Year-over-Year Conference Call Scheduled for today, November 11, 2025, at 5:30 p.m. Eastern Time TAMPA, Fla., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) ("Upexi" or the "Company"), a leading Solana-focused digital asset treasury company and consumer brands owner, today announced record digital asset revenue for the fiscal first quarter ended September 30, 2025. Financial Highlights for the Quarter Ended September 30, 2025 Total revenue for the quarter was $9.2 mill

    11/11/25 5:25:00 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi to Host First Quarter 2026 Earnings Call on November 11th at 5:30 p.m. ET

    TAMPA, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a leading Solana-focused digital asset treasury company and consumer brands owner, today announced that it plans to host a conference call and report its financial results for the first quarter 2026 ended September 30, 2025, on Tuesday, November 11, 2025. Additional details are available under the Investor Relations section of the Company's website: https://ir.upexi.com/ Event:Upexi First Quarter 2026 Earnings CallDate:Tuesday, November 11, 2025Time:5:30 p.m. ETLive Call:1-877-407-9716 (U.S. Toll-Free) or 1-201-493-6779 (International)Webcasthttps://ir.upexi.com/news-events/ir-calendar Fo

    11/6/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Upexi Inc.

    SC 13G - UPEXI, INC. (0001775194) (Subject)

    5/31/23 7:05:10 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Upexi Inc.

    SC 13G - UPEXI, INC. (0001775194) (Subject)

    3/10/23 4:37:37 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Upexi Inc. (Amendment)

    SC 13G/A - UPEXI, INC. (0001775194) (Subject)

    3/10/23 4:36:56 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care